https://www.selleckchem.com/pr....oducts/Imatinib-Mesy
Details of all these cases are available in the public domain. In 2 cases a well-characterized exposure-response relationship provided sufficient justification that differences in the shape of the PK profiles were not clinically relevant. In the remaining 3 cases a thorough characterization of the PK profile along with a risk-based approach provided bases for approval.We report an efficient CuPd nanoparticle (NP) catalyst (3 nm CuPd NPs deposited on carbon support) for catalyzing electrochemical allylic alkylation in water/iso
Мне нравится
Комментарий
Перепост
